How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,042 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. The Society of Thoracic Surgeons Practice Guideline on the Prophylaxis and Management of Atrial Fibrillation Associated With General Thoracic Surgery

history of structural cardiac disease including ventricular hypertrophy, systolic dysfunction, or any valve or coronary disease. (Level of evidence A) Antiarrhythmic drugs with the ability to convert AF to sinus rhythm include amiodarone, disopyramide, dofeti- lide, ?ecainide, ibutilide, procainamide, propafenone, quinidine, and sotalol. A series of comparative studies of medical AF patients has established broadly that ?ecain- ide, ibutilide, dofetilide, propafenone, and amiodarone are the most

2011 Society of Thoracic Surgeons

183. Chest Tightness and Asthma in a Young Man

V1-V2 was positive and diagnostic. If not, we do refer those type II patients for procainamide testing (not to be done in the ED, our electrophysiologists team said this could lead to refractory VF). It's also funny that some years ago, we did learn much from... one of the three Brugada brothers, who were working in research and clinical at Montreal Heart. He did a lot of reinforcement, especially to the ECG techs, about how to do those high V1-V2. It would have been interesting to see the result

2016 Dr Smith's ECG Blog

184. Wide Complex Tachycardia

that convert atrial fibrillation to sinus, such as procainamide or ibutilide (and others), but when you have a wide complex very fast tachycardia, it is best to use electrical cardioversion. It is the safest, and keeps you from having to make a definite diagnosis. As long as you can manage procedural sedation, which is very easy in the case of cardioversion because you only need seconds of sedation and amnesia, then cardioversion is the safest method. Even in the ED, the pattern was not recognized (...) guidelines, but it remains in the European guidelines (although I question it's safety due to the partial AV nodal blocker effect). Where I work we don't have neither procainamide nor ibutilide. 2. Do you think vernakalant would work and would it be safe? 3. How would you manage a stable patient with preexcited Afib that you've decided to sedate and DC cardiovert, in a situation where the patient just had a meal. Is it safe to wait a couple of hours with the patient closely monitored (thereby limiting

2016 Dr Smith's ECG Blog

185. A 12 year old with Wide Complex Tachycardia

was always taught, if it's wide, treat it wide. Even though there is no sign of delta wave, or irregularity (afib with wpw), my general inclination would be to avoid av nodal blocking agents or ccb's. Perhaps just go straight to procainamide? That said faced with this case in front of me, I could see myself convincing myself it's probably just svt with abberancy and giving adenosine x 2. I think my personal preference would have been amiodarone or procainamide, any reason NOT to use those?...verapamil

2016 Dr Smith's ECG Blog

186. Sweet 16 (papers of the year for NYGH EMU 2017)

in the ICU with no hope of recovery. This is one of the worst things we can do to people with modern medicine, and we need to be more cognizant of it as a harm. My bottom line: I will not use amiodarone or lidocaine routinely as part of ACLS Other FOAMed commentaries: Procainamide is better than amiodarone for stable ventricular tachycardia Ortiz M, Martín A, Arribas F. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia (...) : the PROCAMIO study. European heart journal. 2016. PMID: Methods: A multicenter, randomized, open-label trial. They included 74 patients with stable ventricular tachycardia (SBP >/= 90 mm Hg, absence of dyspnea at rest, absence of peripheral hypoperfusion and no severe anginal symptoms). Were randomized to either procainamide 10 mg/kg IV over 20 minutes or amiodarone 5 mg/kg over 20 minutes. Results: The primary outcome (major cardiac events within 40 minutes) favoured procainamide: procainamide = 9% vs

2017 First10EM

187. Torsades de Pointes Full Text available with Trip Pro

patient, deliver an unsynchronized shock.) 1 What do you do if the patient is stable? I think it is reasonable to electrically cardiovert stable ventricular tachycardia, but you can also attempt to treat it medically. Torsades de pointes is caused by a prolonged QT. Almost all of the antiarrhythmics that we normally use to treat ventricular tachycardia, such as amiodarone and procainamide, will prolong the QT further, and therefore can make your patient worse. Do not give amiodarone or procainamide

2017 First10EM

189. Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia. (Abstract)

is part of a larger class of ventricular dysrhythmias defined by a rate of at least 120 beats/min with QRS > 120 ms without regularly occurring P:QRS association. Little controversy exists for the treatment of hemodynamically unstable VT. The medical management of hemodynamically stable monomorphic VT is surrounded by controversy. Direct current cardioversion is most efficacious. Guidelines for the treatment of stable VT from the American Heart Association provide a IIa recommendation for procainamide (...) , compared with a IIb recommendation for both amiodarone and sotalol. Studies evaluating procainamide, lidocaine, amiodarone, and sotalol suffer from poor design, difference in inclusion and exclusion criteria, small sample size, and outcome determination. Procainamide demonstrates the greatest efficacy. If procainamide is selected, a maximum dose of 10 mg/kg at 50-100 mg/min intravenous (IV) over 10-20 min should be provided with monitoring of blood pressure and electrocardiogram. Monomorphic VT

2016 Journal of Emergency Medicine

190. Buprenorphine Transdermal System (Butrans)

and/or litigation. • Subjects who are unsuitable for any other reason to receive study medication, in the opinion of the investigator. • Subjects currently using fentanyl (Duragesic) for pain control or Methadone (Amendment 2) • Subjects with congenital Long QT Syndrome or a family member with this condition (Amendment 4) • Subjects receiving Class 1A antiarrhythmic medications (e.g., quinidine, procainamide, disopyramide)(Amendment 4) • Subjects receiving Class III antiarrhythmic medications (e.g., sotalol

2010 FDA - Drug Approval Package

191. Variation in Antiarrhythmic Management of Infants Hospitalized with Supraventricular Tachycardia: A Multi-Institutional Analysis. (Abstract)

database of SVT hospitalizations from 2003 to 2013. High-volume centers (HVC) were defined as those at the upper quartile of admissions. Infants with an ICD-9 code of paroxysmal SVT were included. Antiarrhythmics investigated included amiodarone, atenolol, digoxin, esmolol, flecainide, procainamide, propafenone, propranolol, and sotalol. Frequency of antiarrhythmic use based on center volume was the primary end point. Rate of 30-day SVT readmission was the secondary end point. Analysis of factors

2016 Pediatric Cardiology

192. Is this Type 2 Brugada syndrome/ECG pattern?

dysplasia. Transthoracic echo did not show any evidence of HOCM or right ventricular dysplasia. EF was normal. He had no known family history of sudden cardiac death at a young age. The electrophysiologist was confident that this was not Brugada, that a procainamide challenge test could be done but that this would normally be done only for "unexplained" syncope, not for typical vasovagal syncope. The patient was discharged with no exercise limitations. He left open the possibility of an exercise test

2015 Dr Smith's ECG Blog

193. Novel epigenetic-based therapies useful in cardiovascular medicine Full Text available with Trip Pro

inhibit DNA methyltransferase directly or by reducing its gene expression (e.g., hydralazine and procainamide) are currently under investigation. The anti-proliferative and anti-inflammatory properties of histone deacetylase inhibitors and their cardio-protective effects have been confirmed in preclinical studies. Furthermore, the regulation of the expression of microRNA targets through pharmacological tools is still under development. Indeed, large controlled trials are required to establish whether

2016 World journal of cardiology

194. 18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study

a condition that could, in the opinion of the investigator, affect his or her response to the radiopharmaceutical and related testing procedures; Is deemed likely to be unable to perform all of the imaging procedures for any reason; Has a history of risk factors for torsades de pointes, including clinically significant findings on ECG, or is taking medications known to prolong QT interval such as citalopram ≥ 40 mg/day, disopyramide, dofetilide, ibutilide, procainamide, quinidine, sotalol, or bepridil

2016 Clinical Trials

195. The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus

diagnosis of cirrhosis Liver Dysfunction with AST or ALT liver enzymes > 2x upper limit of normal Chronic Kidney Disease with glomerular filtration rate < 45 ml/min/1.73m2 Anemia with hematocrit < 30% TSH > 5 or < 0.4 mIU/L Coagulopathy, INR > 1.3 Use of warfarin or other new oral anticoagulants (dabigatran, rivaroxaban, apixaban) Use of subcutaneous heparin, enoxaparin, dalteparin Use of class 1 or class 3 anti-arrhythmic medications (disopyramide, procainamide, quinidine, mexilitine, flecanide

2016 Clinical Trials

196. Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 450 ms in females) Lab values that in the opinion of the primary surgeon would prevent surgical resection Patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2016 Clinical Trials

197. Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma

, Transient Ischemic Attack, Cerebral Vascular Accident, pulmonary embolism, uncontrolled chronic hepatic failure, unstable angina pectoris. Anticoagulant therapy with vitamine K antagonists Patients receiving Class 1A (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents Evidence of QTc (corrected QT interval) prolongation on pretreatment ECG (greater than 44ms in males of greater than 450ms in females) Magnesium, potassium and calcium below the lower limit

2016 Clinical Trials

198. Study of APD421 as PONV Treatment (Prior Prophylaxis)

, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin, etc. Patients who have a documented, clinically significant cardiac arrhythmia or congenital long QT syndrome. Patients who are pregnant or breast feeding. Patients being treated with levodopa. Patients diagnosed with Parkinson's disease. Patients who have received emetogenic anti

2016 Clinical Trials

199. Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease

prophylaxis current treatment or treatment within the past 12 weeks with HDAC inhibitors (eg valproate) taking medication that may increase the dose-dependent side effects myelosuppression or QTc interval prolongation. These include, but are not limited to: Class Ia antiarrhythmic agents such as quinidine, procainamide, disopyramide Class III antiarrhythmic drugs such as amiodarone, sotalol, ibutilide Class Ic antiarrhythmics such as flecainide, propafenone penicillamine opioids such as methadone

2016 Clinical Trials

200. Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

by either an ophthalmologist or optometrist. Treatment with any medication that causes QT prolongation or Torsades de Pointes, including but not limited to: amiodarone, amitriptyline, astemizole, cisapride, citalopram dose greater than 20 mg/day, dihydroergotamine, disopyramide, dofetilide, dronedarone, ergotamine, ibutilide, ondansetron or other 5-HT3 (5-hydroxytryptamine) receptor antagonists, pimozide, procainamide, quinidine, quinine, quinolones, ranolazine, risperidone, sotalol, terfenadine

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>